Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $52.73, for a total value of $1,581,900.00. Following the completion of the sale, the chief executive officer now owns 686,062 shares in the company, valued at $36,176,049.26. The trade was a 4.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Andrew Cheng also recently made the following trade(s):

• On Monday, January 27th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.90, for a total value of $1,647,000.00.
• On Tuesday, December 10th, Andrew Cheng sold 7,855 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total value of $241,855.45.
• On Monday, December 2nd, Andrew Cheng sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.09, for a total value of $802,250.00.

Akero Therapeutics Trading Down 2.3 %

Shares of AKRO stock opened at $49.95 on Wednesday. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm has a market capitalization of $3.49 billion, a PE ratio of -13.32 and a beta of -0.11. The stock has a fifty day simple moving average of $33.42 and a two-hundred day simple moving average of $30.24.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently bought and sold shares of AKRO. Mirae Asset Global Investments Co. Ltd. increased its stake in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares in the last quarter. Eastern Bank purchased a new stake in Akero Therapeutics in the 3rd quarter worth $100,000. Summit Financial Wealth Advisors LLC purchased a new stake in Akero Therapeutics in the 3rd quarter worth $205,000. Victory Capital Management Inc. purchased a new stake in Akero Therapeutics in the 3rd quarter worth $211,000. Finally, AlphaQuest LLC increased its stake in Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company’s stock worth $227,000 after buying an additional 8,147 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Canaccord Genuity Group upped their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Citigroup increased their price target on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. HC Wainwright increased their price target on Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, Morgan Stanley raised their target price on Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, Akero Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $75.86.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.